Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cePolyTregs Immunotherapy in Islet Transplantation
NCT05349591Phase 1Withdrawn
- Sponsor
- University of Alberta
- Start
- Aug 2022
- Primary completion
- May 2025
- Modality
- Regulatory T Cells (Tregs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of cePolyTregs in type 1 diabetes mellitus (T1D) (2 arms), sponsored by University of Alberta. Primary endpoint: Adverse Events at 58 weeks. Planned start Aug 2022; status: withdrawn.
02
Drugs
cePolyTregs
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05349591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349591.